Inspire Medical (INSP) analyst forecast and price target
Analyst forecast
Consensus of 19 analyst ratings
Based on 12 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Initiated Coverage | Underweight | $65.00 | Oct 7, 2026 |
| Freedom Capital Markets | Maintained | Buy | $97.00 | Oct 2, 2026 |
| RBC Capital | Maintained | Sector Perform | $75.00 from $60.00 | Oct 1, 2026 |
| Freedom Capital Markets | Maintained | Buy | $97.00 from $71.00 | Sep 21, 2026 |
| Stifel | Maintained | Buy | $80.00 from $75.00 | Sep 11, 2026 |
| Baird | Maintained | Neutral | $59.00 from $54.00 | Aug 4, 2026 |
| Piper Sandler | Maintained | Neutral | $60.00 from $55.00 | Aug 4, 2026 |
| Evercore ISI Group | Maintained | In-Line | $54.00 from $40.00 | Aug 4, 2026 |
| Truist Securities | Maintained | Hold | $62.00 from $54.00 | Aug 4, 2026 |
| Oppenheimer | Upgraded | Perform → Outperform | $85.00 | Aug 4, 2026 |
| Mizuho | Maintained | Outperform | $65.00 from $55.00 | Aug 4, 2026 |
| JP Morgan | Maintained | Neutral | $60.00 from $54.00 | Aug 4, 2026 |
| UBS | Initiated Coverage | Neutral → Sell | $39.00 from $67.00 | Jul 28, 2026 |
| Truist Securities | Maintained | Hold | $54.00 from $50.00 | Jul 16, 2026 |
| Freedom Capital Markets | Initiated Coverage | Buy | $62.00 | Jul 1, 2026 |
| Evercore ISI Group | Downgraded | Outperform → In-Line | $40.00 from $55.00 | Jun 23, 2026 |
| Oppenheimer | Maintained | Perform | — | May 7, 2026 |
| Baird | Maintained | Neutral | $50.00 from $63.00 | May 5, 2026 |
| Mizuho | Maintained | Outperform | $55.00 from $70.00 | May 5, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $56.00 from $70.00 | May 5, 2026 |
Frequently asked questions
What is the price target for INSP stock?
The average 12-month analyst price target for Inspire Medical (INSP) is $66.75, with a high estimate of $97.00 and a low of $39.00, across 12 analysts.
Is INSP a buy, sell, or hold?
Analysts covering Inspire Medical currently average a Hold rating: 4 buy, 11 hold and 4 sell, from 19 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for INSP?
The average price target of $66.75 implies 3.06% downside from the last price of $68.86.
What is the latest analyst rating on INSP?
On Oct 7, 2026, Barclays initiated coverage of Inspire Medical at Underweight with a price target of $65.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.